EphrinB2 drives perivascular invasion and proliferation of glioblastoma stem-like cells
Benjamin Krusche,
Cristina Ottone,
Melanie P Clements,
Ewan R Johnstone,
Katrin Goetsch,
Huang Lieven,
Silvia G Mota,
Poonam Singh,
Sanjay Khadayate,
Azhaar Ashraf,
Timothy Davies,
Steven M Pollard,
Vincenzo De Paola,
Federico Roncaroli,
Jorge Martinez-Torrecuadrada,
Paul Bertone,
Simona Parrinello
Affiliations
Benjamin Krusche
Cell Interactions and Cancer Group, MRC Clinical Sciences Centre (CSC), London, United Kingdom; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, United Kingdom
Cristina Ottone
Cell Interactions and Cancer Group, MRC Clinical Sciences Centre (CSC), London, United Kingdom; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, United Kingdom
Melanie P Clements
Cell Interactions and Cancer Group, MRC Clinical Sciences Centre (CSC), London, United Kingdom; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, United Kingdom
Wellcome Trust - Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom; European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, United Kingdom
Katrin Goetsch
Cell Interactions and Cancer Group, MRC Clinical Sciences Centre (CSC), London, United Kingdom; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, United Kingdom
Huang Lieven
Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, United Kingdom; Neuroplasticity and Diseases Group, MRC Clinical Sciences, London, United Kingdom
Silvia G Mota
Proteomics Unit, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
Poonam Singh
Department of Histopathology, Imperial College Healthcare Trust, London, United Kingdom
Sanjay Khadayate
Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, United Kingdom
Azhaar Ashraf
Cell Interactions and Cancer Group, MRC Clinical Sciences Centre (CSC), London, United Kingdom; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, United Kingdom
Timothy Davies
Cell Interactions and Cancer Group, MRC Clinical Sciences Centre (CSC), London, United Kingdom; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, United Kingdom
Steven M Pollard
MRC Centre for Regenerative Medicine, The University of Edinburgh, Edinburgh, United Kingdom
Vincenzo De Paola
Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, United Kingdom; Neuroplasticity and Diseases Group, MRC Clinical Sciences, London, United Kingdom
Federico Roncaroli
Department of Histopathology, Imperial College Healthcare Trust, London, United Kingdom; Wolfson Molecular Imaging Centre, University of Manchester, Manchester, United Kingdom
Jorge Martinez-Torrecuadrada
Proteomics Unit, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
Paul Bertone
Wellcome Trust - Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom; European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, United Kingdom
Cell Interactions and Cancer Group, MRC Clinical Sciences Centre (CSC), London, United Kingdom; Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, United Kingdom
Glioblastomas (GBM) are aggressive and therapy-resistant brain tumours, which contain a subpopulation of tumour-propagating glioblastoma stem-like cells (GSC) thought to drive progression and recurrence. Diffuse invasion of the brain parenchyma, including along preexisting blood vessels, is a leading cause of therapeutic resistance, but the mechanisms remain unclear. Here, we show that ephrin-B2 mediates GSC perivascular invasion. Intravital imaging, coupled with mechanistic studies in murine GBM models and patient-derived GSC, revealed that endothelial ephrin-B2 compartmentalises non-tumourigenic cells. In contrast, upregulation of the same ephrin-B2 ligand in GSC enabled perivascular migration through homotypic forward signalling. Surprisingly, ephrin-B2 reverse signalling also promoted tumourigenesis cell-autonomously, by mediating anchorage-independent cytokinesis via RhoA. In human GSC-derived orthotopic xenografts, EFNB2 knock-down blocked tumour initiation and treatment of established tumours with ephrin-B2-blocking antibodies suppressed progression. Thus, our results indicate that targeting ephrin-B2 may be an effective strategy for the simultaneous inhibition of invasion and proliferation in GBM.